JPWO2019199861A5

JPWO2019199861A5 -

Info

Publication number: JPWO2019199861A5
Application number: JP2021505184A
Authority: JP
Publication date: 2022-04-21

Claims

A pharmaceutical composition comprising a hemp extract and a carrier, wherein the hemp extract is:
Cannabidiol;
And cannabidiol acid,
The ratio of cannabidiol to cannabidiol acid is from about 0.6: 1 to about 1: 0.6.
Pharmaceutical composition.

A pharmaceutical composition comprising a hemp extract and a carrier, wherein the hemp extract is:
α-Pinene;
β-myrcene;
β-Pinene;
δ-limonene;
Linalool;
β-caryophyllene;
α-Humulene;
Nerolidol 2;
Guaiol;
Caryophyllene oxide;
And a pharmaceutical composition comprising 4 or more of α-bisabolol.

A pharmaceutical composition comprising a hemp extract and a carrier, wherein the hemp extract is:
Cannabidiol;
Cannabidiol acid;
Cannabigerol acid;
Δ9-Tetrahydrocannabinol;
as well as
Cannabichromene
Including
A pharmaceutical composition in which the carrier is grape seed oil.

The pharmaceutical according to claim 3, wherein the ratio of cannabidiol to cannabidiol acid is selected from the group consisting of about 1: 100, about 1:50, about 1:10, and about 1: 1. Composition.

The pharmaceutical composition according to claim 3 or 4, wherein the ratio of cannabidiol to cannabidiol acid is about 1: 1.

The hemp extract is
Cannabigerol acid;
Δ9-Tetrahydrocannabinol;
as well as
Cannabichromene
The pharmaceutical composition according to claim 1 or 2, further comprising.

Cannabidiol;
Cannabidiol acid;
Cannabigerol acid;
Δ9-Tetrahydrocannabinol;
as well as
Cannabichromene
A pharmaceutical composition comprising.

The pharmaceutical composition according to claim 7, further comprising a carrier.

The pharmaceutical composition according to claim 7, wherein cannabidiol; cannabidiol acid; cannabigerol acid; Δ9-tetrahydrocannabinol; and cannabichromene are contained in the hemp extract.

The hemp extract is
α-Pinene;
β-myrcene;
β-Pinene;
δ-limonene;
Linalool;
β-caryophyllene;
α-Humulene;
Nerolidol 2;
Guaiol;
Caryophyllene oxide;
The pharmaceutical composition according to any one of claims 1, 3 to 6, and 9, further comprising 4 or more of α-bisabolol.

The pharmaceutical composition according to any one of claims 1 to 10 , wherein the concentration of Δ9-tetrahydrocannabinol is insufficient to produce a psychotropic effect.

The pharmaceutical composition according to any one of claims 3 to 11 , wherein the ratio of Δ9-tetrahydrocannabinol to other cannabinoids is about 1:25.

The concentration of Δ9-tetrahydrocannabinol is less than about 1 mg / mL, or
The concentration of Δ9 -tetrahydrocannabinol is less than about 0.5 mg / mL, or
The concentration of Δ9 -tetrahydrocannabinol is less than about 0.3 mg / mL, or
The concentration of Δ9 -tetrahydrocannabinol is less than about 0.2 mg / mL, or
The concentration of Δ9 -tetrahydrocannabinol is less than about 0.1 mg / mL, or
The concentration of Δ9 -tetrahydrocannabinol is about 0 mg / mL.
The pharmaceutical composition according to any one of claims 3 to 12 , wherein the pharmaceutical composition is characterized by the above.

The hemp extract is
About 1-10 mg / mL cannabidiol;
About 1-10 mg / mL cannabidiol acid;
Approximately 0.05-0.2 mg / mL cannabigerol acid;
Approximately 0.1-0.3 mg / mL Δ9-tetrahydrocannabinol;
And containing about 0.1-0.4 mg / mL cannabichromene,
Or
In some cases, the hemp extract may be
Approximately 5 mg / mL cannabidiol;
Approximately 5 mg / mL cannabidiol acid;
Approximately 0.11 mg / mL cannabigerol acid;
Approximately 0.25 mg / mL Δ9-tetrahydrocannabinol;
The pharmaceutical composition according to any one of claims 1 to 6 and 9 to 13, which comprises about 0.27 mg / mL cannabichromene.

The hemp extract is
Approximately 0.09-0.13% α-pinene;
Approximately 0.23 to 0.44% β-myrcene;
Approximately 0.04 to 0.09% β-pinene;
Approximately 0.05-0.09% δ-limonene:
Approximately 0.03 to 0.06% linalool;
Approximately 0.04 to 0.07% β-caryophyllene;
Approximately 0.02-0.04% α-humulene;
Approximately 0.04 to 0.07% nerolidol 2;
Approximately 0.02-0.04% guaiol;
Approximately 0.04 to 0.08% caryophyllene oxide;
The pharmaceutical composition according to any one of claims 1 to 6 and 9 to 13, which comprises about 0.01 to 0.04% of α-bisabolol.

The hemp extract is
Camphene;
β-Ocimene;
Eucalyptus;
Isopulegol;
And / or nerolidol 1
Including,
as well as
The hemp extract is
About 0.02% camphene;
Approximately 0.02-0.03% β-ocimene;
Approximately 0.02-0.05% eucalyptus;
Approximately 0.02% isopulegol;
And / or about 0.02-0.04% nerolidol 1
The pharmaceutical composition according to any one of claims 3 to 6 and 9 to 15, wherein the pharmaceutical composition comprises.

The hemp extract is α-pinene, β-myrcene, β-pinene, δ-limonene, linalool, β-caryophyllene, α-humulene, nerolidol 2, guaiol, caryophyllene oxide, α-bisabolol, camphene, β-ocimene. , Eucalyptor, Isopregor, and Nerolidol 1, 5, 6, 7, 8, 9, 10, 11, 12, 12, 13, 14, 15, or more. The pharmaceutical composition according to any one of claims 3 to 6 and 9 to 16, wherein the pharmaceutical composition comprises.

The pharmaceutical composition according to any one of claims 1 to 17, wherein the composition is blended in a carrier.
The carrier is selected from the group consisting of linseed oil, olive oil, fish oil, salmon oil, coconut oil, canine pepper oil, sesame oil, and grape seed oil.
In some cases
The carrier is grape seed oil,
Or
The pharmaceutical composition, wherein the carrier is catnip oil.

The pharmaceutical composition according to any one of claims 1 to 18, wherein the composition contains nepetalactone and / or taurine.

The pharmaceutical composition according to any one of claims 1 to 19, wherein the composition is formulated for administration using a nebulizer, a diffuser, or a pet collar. ..

The pharmaceutical composition according to any one of claims 1 to 19 , wherein the composition is formulated as a collar for pets or a chewing agent for oral administration.

The weight of the chewing agent is about 0.5 to 10 g.
In some cases
The weight of the chewing agent is about 4 g, about 6 g, about 9 g, or about 10 g.
And / or
The weight of the chewing agent is about 4 g.
21. The pharmaceutical composition according to claim 21 .

The chewing agent is
Cannabidiol about 7 mg;
Cannabidiol acid about 6 mg;
Cannabigerol acid about 0.12 mg;
Δ9-Tetrahydrocannabinol about 0.32 mg;
And cannabichromene about 0.36 mg
22. The pharmaceutical composition according to claim 22 .

The pharmaceutical composition according to any one of claims 1 to 23,
Also, a dosage form comprising one or more pharmaceutically acceptable additives, fragrances, surfactants, and adjuvants.

24. The agent of claim 24 , wherein the ratio of cannabidiol to cannabidiol acid is selected from the group consisting of about 1: 100, about 1:50, about 1:10, and about 1: 1. shape.

Formulated as a chewing agent for oral administration, formulated as a sublingual spray, formulated as a water or alcohol-soluble solution, gel, or cream for transdermal application. Formulated as a gel for buccal or mucosal administration, formulated as a powder, formulated as a solution for subcutaneous injection, formulated as a tablet, formulated as a capsule. 24 or 25 , wherein it is formulated, formulated as a rigid chewable agent, formulated in a carrier for oral administration, and / or formulated for inhalation. The dosage form.

26. The dosage form of claim 26 , wherein the chewing agent is manufactured using cold extrusion.

The carrier is selected from the group consisting of linseed oil, olive oil, fish oil, salmon oil, coconut oil, canine pepper oil, sesame oil, and grape seed oil.
In some cases
The carrier is grape seed oil;
The carrier is catnip oil.
26. The dosage form according to claim 26 .

Glucosamine HCl;
Chondroitin sulfate (76%);
Saccharomyces cerevisiae;
Gum arabic;
Guar gum;
Fragrance;
Verdilox;
Previon;
Hemp extract;
Glycerin;
Sunflower lecithin;
And a dosage form characterized by containing water.

Approximately 12-17% glucosamine HCl;
Approximately 1-4% chondroitin sulfate (76%);
About 29-33% brewer's yeast;
About 3-6% gum arabic;
About 0.5-2% guar gum;
Approximately 12-16% fragrance;
Approximately 0.01-0.1% Verdirox;
Approximately 0.5-1.5% Previon;
About 3-6% hemp extract;
About 13-17% glycerin;
Approximately 3-7% sunflower lecithin;
And contains about 3-7% water,
In some cases
Approximately 15.6% glucosamine HCl;
Approximately 2.6% chondroitin sulfate (76%);
About 30% brewer's yeast;
Approximately 4.7% gum arabic;
About 0.9% guar gum;
Approximately 14.2% fragrance;
Approximately 0.05% Verdirox;
Approximately 0.9% Previon;
Approximately 4.7% hemp extract;
Approximately 15.1% glycerin;
Approximately 5.7% sunflower lecithin;
29. The dosage form of claim 29 , which comprises about 5.7% water.

Glucosamine HCl;
hyaluronic acid;
Saccharomyces cerevisiae;
Gum arabic;
Guar gum;
Fragrance;
Verdilox;
Previon;
Hemp extract;
Glycerin;
Sunflower lecithin;
And a dosage form characterized by containing water.

Approximately 12-17% glucosamine HCl;
About 0.01-1% hyaluronic acid;
About 29-33% brewer's yeast;
About 3-6% gum arabic;
About 0.5-2% guar gum;
Approximately 12-16% fragrance;
Approximately 0.01-0.1% Verdirox;
Approximately 0.5-1.5% Previon;
About 3-6% hemp extract;
About 13-17% glycerin;
Approximately 3-7% sunflower lecithin;
And contains about 3-7% water,
In some cases
Approximately 16% glucosamine HCl;
About 0.1% hyaluronic acid;
About 30.6% brewer's yeast;
Approximately 4.8% gum arabic;
Approximately 0.97% guar gum;
Approximately 14.5% fragrance;
Approximately 0.05% Verdirox;
Approximately 0.97% Previon;
Approximately 4.8% hemp extract;
Approximately 15.5% glycerin;
Approximately 5.8% sunflower lecithin;
31. The dosage form of claim 31 , characterized by containing about 5.8% water.

Hemp extract;
peanut butter;
Rice bran;
Glucosamine HCL;
sweet potato;
Dried molasses;
Sorbic acid brewer's yeast;
sugar;
water;
Glycerin;
Potato starch;
Dehydrated peanut butter;
Rice starch;
And a dosage form comprising guar gum.

Approximately 5.0% hemp extract;
About 15.0% peanut butter;
About 12.5% rice bran;
Approximately 12.75% Glucosamine HCL;
About 5.5% sweet potatoes;
Approximately 8.0% dried molasses;
About 1% sorbic acid;
About 5.0% brewer's yeast;
Approximately 6.0% sugar;
Approximately 9.25% water;
About 13.0 glycerin;
About 2.0% potato starch;
About 1.0% dehydrated peanut butter;
About 2.0% rice starch;
And contains about 2.0% guar gum,
In some cases
Approximately 5.0% hemp extract;
About 15.0% peanut butter;
About 13.0% rice bran;
Approximately 8.5% Glucosamine HCL;
About 6.0% sweet potatoes;
Approximately 9.0% dried molasses;
About 1% sorbic acid;
About 5.0% brewer's yeast;
Approximately 6.0% sugar;
Approximately 9.5% water;
About 13.0 glycerin;
About 4.0% potato starch;
About 1.0% dehydrated peanut butter;
About 2.0% rice starch;
And contains about 2.0% guar gum,
And in some cases
Approximately 3.0-10.0% hemp extract;
Approximately 10.0-20.0% peanut butter;
About 10.0 to 15.0% rice bran;
Approximately 5.0-15.0% glucosamine HCL;
Approximately 4.0-10.0% sweet potatoes;
Approximately 6.0-13.0% dried molasses;
Approximately 0.5-5.0% sorbic acid;
Approximately 2.0-8.0% brewer's yeast;
Approximately 3.0-8.0% sugar;
Approximately 5.0-15.0% water;
Approximately 8.0-18.0% glycerin;
Approximately 1.0-8.0% potato starch;
About 0.5-5.0% dehydrated peanut butter;
About 1.0-5.0% rice starch;
33. The dosage form of claim 33 , characterized by comprising about 1.0-5.0% guar gum.

The dosage form according to claim 33 or 34 , wherein the dosage form contains about 5.0% hemp extract.

The flavoring agent is selected from the group consisting of catnip oil, chicken liver powder, poultry meat extract, maltodextrin, butter, and bacon .
The flavoring agent is chicken liver powder or
The flavoring agent is catnip oil.
The dosage form according to any one of claims 29 to 32 .

The dosage form according to any one of claims 29 to 36 , wherein the dosage form contains nepetalactone and taurine.

The dosage form according to any one of claims 29 to 37 , which is formulated as a chewing agent for oral administration .
The chewing agent is a dosage form manufactured using cold extrusion.

The composition according to any one of claims 1 to 23 , or claims 24 to 38 , characterized in the manufacture of a pharmaceutical agent for treating or alleviating pain in a required veterinary subject. Use of the dosage form described in any one of the paragraphs.

The pain is characterized by being associated with arthritis, postoperative pain, acute pain, toothache, pain with gingival inflammation, or polyarthralgia. The use according to item 39 .

The pharmaceutical composition or dosage form is formulated to be administered twice daily at a dose of about 1.0 mg / kg.
The pharmaceutical composition or dosage form is formulated to be administered at a dose of about 1.0 mg / kg three times daily.
The pharmaceutical composition or dosage form is formulated to be administered twice daily at a dose of about 2.0 mg / kg.
The pharmaceutical composition or dosage form is formulated or formulated to be administered at a dose of about 2.0 mg / kg three times daily.
The use according to claim 39 or 40 , wherein the pharmaceutical composition or dosage form is formulated to be administered at a dose of about 0.1-8.0 mg / kg.

The pharmaceutical composition or dosage form is formulated to be administered at twice the therapeutically effective dose for one week and then to be administered at a therapeutically effective dose.
The therapeutically effective dose is about 0.1-0.5 mg / kg.
The therapeutically effective dose is about 2 mg / kg, or
The therapeutically effective dose is about 8 mg / kg.
The use according to any one of claims 39 to 41 , characterized in that .

The pharmaceutical composition or dosage form is formulated to be administered at a dose of about 1 mg / kg over a week, and then formulated to be administered at a dose of about 0.1 to 0.5 mg / kg. The use according to any one of claims 39 to 41 .

39. The pharmaceutical composition or dosage form is formulated to be administered at a dose of about 4 mg / kg over a week, and then to be administered at a dose of about 2 mg / kg. Use according to any one of 41 .

The above use yielded a therapeutically effective median maximum serum concentration of cannabidiol .
The median maximum serum concentration of cannabidiol is about 102 ng / mL.
Or
The median maximum serum concentration of cannabidiol is about 590 ng / mL.
The use according to any one of claims 39 to 44 , characterized in that .

The veterinary subject is a dog, cat, cow, pig, or horse.
In some cases
The veterinary subject is a dog, or
The veterinary subject is a cat
The use according to any one of claims 39 to 45 , characterized in that .

It is characterized in the manufacture of a pharmaceutical for treating or alleviating arthritic pain, postoperative pain, acute pain, toothache, gingival pain, or polyarthralgia in a required veterinary subject. , Use of asa extract .

The use according to claim 47 , wherein the hemp extract is formulated to be administered at a dose of about 0.1-8.0 mg / kg.

The hemp extract was formulated to be administered at twice the therapeutically effective dose over a week, followed by a therapeutically effective dose.
The therapeutically effective dose is about 0.1-0.5 mg / kg .
The therapeutically effective dose is about 1 mg / kg .
The therapeutically effective dose is about 2 mg / kg .
Or
The therapeutically effective dose is about 8 mg / kg.
The use according to claim 47 or 48 , characterized in that .

The hemp extract was formulated to be administered at a dose of about 1 mg / kg over a week, and then formulated to be administered at a dose of about 0.1-0.5 mg / kg.
In some cases
The hemp extract is formulated to be administered at a dose of about 4 mg / kg over a week and then to be administered at a dose of about 2 mg / kg .
47. The use according to claim 47 .

The above use yielded a therapeutically effective median maximum serum concentration of cannabidiol .
The median maximum serum concentration of cannabidiol is about 102 ng / mL .
Or,
The median maximum serum concentration of cannabidiol is about 590 ng / mL.
The use according to any one of claims 47 to 50 , characterized in that .

The veterinary subject is a dog, cat, cow, pig, or horse.
In some cases
The veterinary subject is a dog ,
Or,
The veterinary subject is a cat
The use according to any one of claims 47 to 51 , characterized in that .

Use of hemp extract, characterized in the manufacture of pharmaceuticals to achieve a 0-24 hour curve area of 42.4-3048 ng hours / ml for cannabidiol in veterinary subjects.

The use according to claim 53 , wherein the subject is a dog or a cat.

A pharmaceutical composition comprising a hemp extract and a carrier, wherein the hemp extract is:
Cannabidiol;
And cannabidiol acid,
The ratio of cannabidiol to cannabidiol acid is from about 0.6: 1 to about 1: 0.6.
The hemp extract does not contain terpenes,
Pharmaceutical composition.